Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for advances in Alzheimer’s disease made in 2001 and projects future breakthroughs over the next 20 years.
Posted in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in -
Julie Zissimopoulos to Co-Chair 2023 NIA National Research Summit on Care, Services and Support for Persons Living with Dementia
The summit provides coordinated planning efforts that respond to the national plan to address Alzheimer’s Disease.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
2023 Alzheimer’s Trial Recruitment Innovation Lab Fellowship Program — Application Open
The University of Southern California (USC) announces an opening for a fellow to join the Alzheimer’s Trial Recruitment Innovation Lab (ATRIL) fellowship program in the fall of 2023.
-
2023 Clinical Trial Recruitment Lab (CTRL) Request for Pilot Project Proposals
CTRL is seeking proposals for pilot projects that test strategies and solutions designed to address barriers to recruitment for Alzheimer’s disease clinical trials.
-
Social and Biomedical Scientists Come Together to Address the Burden of Alzheimer’s Disease
Social scientists are uniquely poised to evaluate the implications of Alzheimer’s costs, yet they often lack knowledge of the biomedical foundations of the disease.
Categorized in Articles -
Cost-Effectiveness Models for Alzheimer’s Disease and Related Dementias: IPECAD Modeling Workshop Cross-Comparison Challenge
Researchers established a collaboration framework to assess cost-effectiveness outcomes, an important step toward transparent and credible Alzheimer’s Disease models.
-
CMS’s Alzheimer’s Coverage Policy Will Inhibit Access and Discourage Innovation
Individuals in underserved communities have to travel long distances, well beyond the 30-minute standard, to access clinical trial sites for Aduhelm.
Categorized in Evidence Base -
Interdisciplinary Panel Offers Solutions to Improve Recruitment for Alzheimer’s Clinical Trials
Experts from the private and public sectors convened a panel to improve recruitment for Alzheimer’s clinical trials.